Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
E-pub ahead of print

Characteristics of pregnant women with diabetes using injectable glucose-lowering drugs in the EVOLVE study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Neonatal complications and neurophysiological development in twins - a long-term follow-up study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Sertraline use during pregnancy and effect on fetal cardiac function

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Prediction of preeclampsia in type 1 diabetes in early pregnancy by clinical predictors: a systematic review

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Elisabeth R Mathiesen
  • Norsiah Ali
  • Eleni Anastasiou
  • Katarzyna Cypryk
  • Harold W de Valk
  • Jorge M Dores
  • Fidelma P Dunne
  • Magnus Ekelund
  • Santiago Durán García
  • Hélène Hanaire
  • Lise Lotte N Husemoen
  • Marina Ivanisevic
  • Hans-Peter Kempe
  • Rikke B Nordsborg
  • David R McCance
View graph of relations

AIMS: To examine clinical parameters, glycemic control, folic acid supplementation, and the presence of other chronic diseases during early pregnancy in the EVOLVE study population (women with pre-existing diabetes treated with injectable glucose-lowering drugs).

METHODS: Cross-sectional baseline evaluation of EVOLVE: an international, multicenter, non-interventional study investigating the safety of injectable glucose-lowering drugs in pregnant women with pre-existing type 1 (T1D) or type 2 diabetes (T2D). Data were collected at enrollment visit interviews before gestational week 16.

RESULTS: In total, 2383 women from 17 mainly European countries were enrolled in the study: 2122 with T1D and 261 with T2D; mean age was 31 and 33 years, and duration of diabetes was 15 and 6 years, respectively. For women with T1D or T2D, 63% and 75%, respectively, received basal and rapid-acting insulin, 36% and 3% rapid-acting insulin only, 0.7% and 14.0% basal insulin only, 0.2% and 5.4% premix insulin, 0.0% and 1.2% injectable glucagon-like peptide-1 receptor agonist treatment without insulin. In women with T1D or T2D, respectively, during early pregnancy, 59% and 62% had HbA1c <7.0% (53 mmol/mol); 16% and 36% reported not taking folic acid before or during early pregnancy. Overall, >40% of women had ≥1 chronic concomitant condition (predominantly thyroid disease or hypertension). Retinopathy was the most commonly reported diabetic complication. The most commonly reported previous pregnancy complication was miscarriage.

CONCLUSIONS: Baseline data from this large multinational population of women with pre-existing diabetes indicate that sub-optimal glycemic control, poor pregnancy planning, and chronic concomitant conditions were common in early pregnancy.

Original languageEnglish
JournalThe journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
Pages (from-to)1-9
Number of pages9
Publication statusE-pub ahead of print - 2022

    Research areas

  • Pregnancy, insulin, type 1 diabetes, type 2 diabetes, EVOLVE study

ID: 74731279